Panion & Bf Biotech Inc.
TWSE:1760.TW
86.4 (TWD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,881.875 | 2,398.648 | 1,901.211 | 1,568.637 | 1,573.944 | 1,408.741 | 1,212.478 | 1,049.246 | 1,205.065 | 1,014.406 | 857.082 | 674.896 | 584.249 | 524.779 | 559.396 |
| Cost of Revenue
| 969.311 | 1,080.052 | 989.073 | 754.605 | 709.637 | 605.358 | 518.099 | 460.765 | 469.171 | 405.334 | 392.276 | 326.957 | 282.524 | 230.918 | 262.179 |
| Gross Profit
| 912.564 | 1,318.596 | 912.138 | 814.032 | 864.307 | 803.383 | 694.379 | 588.481 | 735.894 | 609.072 | 464.806 | 347.939 | 301.725 | 293.861 | 297.217 |
| Gross Profit Ratio
| 0.485 | 0.55 | 0.48 | 0.519 | 0.549 | 0.57 | 0.573 | 0.561 | 0.611 | 0.6 | 0.542 | 0.516 | 0.516 | 0.56 | 0.531 |
| Reseach & Development Expenses
| 217.041 | 248.496 | 157.711 | 127.016 | 103.418 | 110.686 | 103.636 | 67.774 | 80.063 | 57.987 | 38.701 | 48.633 | 50.581 | 52.553 | 25.167 |
| General & Administrative Expenses
| 175.937 | 233.907 | 190.322 | 161.776 | 172.204 | 170.641 | 138.165 | 119.984 | 155.758 | 157.525 | 112.089 | 105.641 | 106.635 | 107.735 | 101.158 |
| Selling & Marketing Expenses
| 425.642 | 422.151 | 396.673 | 398.386 | 345.233 | 299.878 | 307.855 | 274.277 | 340.973 | 329.163 | 300.135 | 241.375 | 191.932 | 188.966 | 166.969 |
| SG&A
| 538.694 | 656.058 | 586.995 | 560.162 | 517.437 | 470.519 | 446.02 | 394.261 | 496.731 | 486.688 | 412.224 | 347.016 | 298.567 | 296.701 | 268.127 |
| Other Expenses
| 30.734 | -66.582 | 43.526 | 18.909 | 19.531 | 34.877 | 2.088 | 4.081 | -1.084 | 9.932 | 14.421 | 8.662 | 15.913 | 14.351 | 12.773 |
| Operating Expenses
| 755.735 | 904.554 | 744.706 | 706.087 | 640.386 | 591.413 | 549.656 | 458.86 | 615.929 | 544.675 | 450.925 | 395.649 | 349.148 | 349.254 | 293.294 |
| Operating Income
| 156.829 | 341.072 | 199.423 | 97.316 | 228.112 | 211.97 | 144.723 | 129.621 | 119.965 | 64.397 | 13.881 | -47.71 | -47.423 | -55.393 | 3.923 |
| Operating Income Ratio
| 0.083 | 0.142 | 0.105 | 0.062 | 0.145 | 0.15 | 0.119 | 0.124 | 0.1 | 0.063 | 0.016 | -0.071 | -0.081 | -0.106 | 0.007 |
| Total Other Income Expenses Net
| 25.897 | -7.663 | -16.771 | -7.91 | -1.818 | 32.408 | -1.584 | -0.197 | -3.777 | 10.171 | 9.318 | 3.134 | 6.991 | 19.343 | 7.871 |
| Income Before Tax
| 182.726 | 333.409 | 182.652 | 89.406 | 226.294 | 244.378 | 143.139 | 129.424 | 116.188 | 74.568 | 23.199 | -44.576 | -40.432 | -36.05 | 11.794 |
| Income Before Tax Ratio
| 0.097 | 0.139 | 0.096 | 0.057 | 0.144 | 0.173 | 0.118 | 0.123 | 0.096 | 0.074 | 0.027 | -0.066 | -0.069 | -0.069 | 0.021 |
| Income Tax Expense
| 91.492 | 151.064 | 78.25 | 61.505 | 64.965 | 85.207 | 52.6 | 39.704 | 43.192 | 27.089 | 7.547 | 9.367 | 5.581 | 16.518 | 10.554 |
| Net Income
| 77.219 | 182.345 | 104.402 | 27.901 | 161.329 | 159.171 | 90.539 | 89.72 | 72.996 | 48.269 | 18.149 | -40.562 | -36.26 | -39.305 | 5.088 |
| Net Income Ratio
| 0.041 | 0.076 | 0.055 | 0.018 | 0.102 | 0.113 | 0.075 | 0.086 | 0.061 | 0.048 | 0.021 | -0.06 | -0.062 | -0.075 | 0.009 |
| EPS
| 0.9 | 2.13 | 1.32 | 0.36 | 2.07 | 2.06 | 1.31 | 1.3 | 1.06 | 0.71 | 0.3 | -0.77 | -0.64 | -0.7 | 0.1 |
| EPS Diluted
| 0.9 | 2.12 | 1.32 | 0.36 | 2.07 | 2.05 | 1.31 | 1.29 | 1.06 | 0.7 | 0.29 | -0.76 | -0.64 | -0.7 | 0.1 |
| EBITDA
| 327.219 | 504.619 | 343.046 | 181.458 | 296.481 | 285.078 | 184.857 | 171.958 | 149.106 | 100.465 | 51.496 | -17.766 | -13.889 | -12.332 | 40.324 |
| EBITDA Ratio
| 0.174 | 0.21 | 0.18 | 0.116 | 0.188 | 0.202 | 0.152 | 0.164 | 0.124 | 0.099 | 0.06 | -0.026 | -0.024 | -0.023 | 0.072 |